SPAGO — Spago Nanomedical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK88.14m
- SEK62.21m
- SEK0.44m
Brief: Spago Nanomedical Carries Out Rights Issue
Brief: Spago Sees SpagoPix U.S. Patent Protection Extended
Brief: Spago Nanomedical Q1 Loss For Quarter Widens To SEK 9.9 Mln
Brief: Spago Nanomedical Gets Extended SpagoPix Patent Protection In Japan
Brief: Spago Nanomedical Q4 Loss Widens To SEK 11.3 Mln
Brief: Spago Nanomedical Preclinical Results Show Reduced Tumor Growth With TUMORAD®
Brief: Spago Nanomedicals Expands Study With Spagopix Into New Indications Based On Results
Brief: Spago Nanomedical: Tumorad Shows Good Safety In Preclinical Studies
Brief: Spago Nanomedical Q3 Loss Widens To SEK 10.1 Mln
Brief: Spago Selects Cmed As CRO For Clinical Trial With Tumorad
Brief: Spago Nanomedical Q2 Loss Widens To SEK 11.6 Mln
Brief: Spago Nanomedical Carries Out Rights Issue And Initiates Listing Change Process
Brief: Spago: Extended Patent Protection For Spagopix In Europe
Brief: Spago Nanomedical: Interim Results From Study On SpagoPix Show Clear Contrast In MR-Images
Brief: Spago April-September Net Loss Narrows To SEK 4.5 Million
Brief: Spago Nanomedical: Healthinvest Sells Its Stake In Co
Brief: Spago Nanomedical Q2 Net Loss Widens To SEK 4.8 Mln
Brief: Spago Nanomedical Names Candidate-Drug In Tumorad Project
Brief: Spago Nanomedical Updates On Preclinical Studies Of Tumorad